Pharmaceutical Companies Spend More on PR than on Disease
Title: "Disease Mongering"
By: Bob Burton and Andy Rowell
Source: PR Watch, First Quarter 2003
Researched by: Erin Cossen
http://www.projectcensored.org/newsflash/newsflash.html#prdisease
The pharmaceutical industry spends twice as much on public relations and marketing than it does on drug research and development. During the year 2000 more than $13.2 billion was spent on pharmaceutical marketing in the U.S. Drug companies such as Pfizer, GlaxoSmithKline, Merck, and Astra Zeneca hire specialist "healthcare" PR companies to help create profits.
The leading healthcare PR companies in the U.S. are Edelman, Ruder Finn and Chandler Chicco Agency. These groups are responsible for persuading doctors and patients to use products from the various companies that they represent. Patient groups are wooed to assist with disease awareness campaigns." They also organize medical conferences to provide a platform for well trained "product champions" to announce promising results of drug research.
PR firms aim to create "buzz" about the new drug in order to increased sales. Chandler Chicco Agency had much success with this when they created the buzz over Pfizer's $1 billion-a-year impotence drug, Viagra.
Advertising for drug companies tends to overemphasize the benefits of medication. Other strategies for dealing with problems are ignored. Diseases are created to create new markets for new drugs. Patient groups are created to boost a new drug that is about to emerge from the drug company's "pipeline."
An investigation by the Journal of the American Medical Association found that it is commonplace practice for articles to be "ghostwritten" by PR firms for well-respected medical researchers. This creates a market for new products by creating dissatisfaction with existing products.